Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma

Journal of Clinical Oncology

Volumn 20, Issue 22, 2002, Pages 4413-4419

  Kaiser, Ulrich ^a   Uebelacker, Irmgard ^a   Abel, Ulrich ^a   Birkmann, Josef ^a   Trümper, Lorenz ^a   Schmalenberg, Harald ^a   Karakas, Tunca ^a   Metzner, Bernd ^a   Hossfeld, Dieter K ^a   Bischoff, Helge G ^a   Franke, Astrid ^a   Reiser, Marcel ^a   Müller, Peter ^a   Mantovani, Luisa ^a   Grundeis, Marc ^a   Rothmann, Frank ^a   Von Seydewitz, Cay Uwe ^a   Mesters, Rolf M ^a   Steinhauer, Ernst U ^a   Krahl, Dorothea ^a   Schumacher, Kurt ^a   Kneba, Michael ^a   Baudis, Michael ^a   Schmitz, Norbert ^a   Pfab, Rüdiger ^a   Köppler, Hubert ^a   Parwaresch, Reza ^a   Pfreundschuh, Michael ^a   Havemann, Klaus ^a   more..

^a ST BERNWARD KRANKENHAUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; PREDNISONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BILE DUCT CARCINOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; FOLLOW UP; GERMANY; HUMAN; HUMAN CELL; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SHORT COURSE THERAPY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; GERMANY; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; PREDNISOLONE; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RISK; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0037111830     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.07.075     Document Type: Article

References (17)

1. Armitage JO: Treatment of non-Hodgkin's lymphomas. N Engl J Med 328:1023-1030, 1993
2. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
3. Nademee A, Schmidt GM, O'Donnell MR, et al: High dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: A pilot study. Blood 80:1130-1134, 1992
4. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
5. Köppler H, Pflüger KH, Eschenbach I, et al: CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: A phase II multicentre study. Br J Cancer 60:79-82, 1989
6. Köppler H, Pflüger KH, Eschenbach I, et al: Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: Treatment results and prognostic factor analysis in a multicentre trial. Ann Oncol 5:49-55, 1994
7. Stansfeld AG, Diebold J, Noel H, et al: Updated Kiel classification for lymphoma. Lancet 1:292-293, 1988 (letter)
8. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
9. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
10. Haioun C, Lepage E, Gisselbrecht C, et al: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediategrade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients. J Clin Oncol 12:2543-2551, 1994
11. Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH-87-2 protocol - A Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 18:3025-3030, 2000
12. Gisselbrecht C, Lepage E, Molina T, et al: Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20:2472-2479, 2002
13. Santini G, Salvagno L, Leoni T, et al: VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 16:2796-2802, 1998
14. Gianni AM, Bregni M, Siena S, et al: High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297, 1997
15. Kluin-Nelemans H, Zagonel V, Anastasopoulou A, et al: Standard chemotherapy with or without high-dose chemotherapy for aggressive Non-Hodgkin's lymphoma: Randomized phase III EORTC study. J Natl Cancer Inst 93:22-30, 2001
16. Martelli M, Vignetti M, Zinzanni P, et al: High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: A prospective randomized Italian multicenter study. J Clin Oncol 14:534-542, 1996
17. Verdonck LF, van Putten WLJ, Hagenbeck A, et al: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332:1045-1051, 1995